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ABSTRACT 
Background and Objectives: Ventricular assist systems are used in patients with end-stage heart failure to pro-
long life or as a bridge to transplantation. Several types of ventricular assist systems have been developed and they 
are now being used. We developed a new Biomedlab® electro-mechanical implantable ventricular assist device 
(IVAD) and we performed in vivo experimentation to evaluate the durability and safety of the device, as well as 
its hematologic effect. Materials and Methods: We implanted the newly developed IVAD in the pre-peritoneal 
cavity of 5 Hallstein calves. The inflow tract was inserted through the left ventricular apex, and the outflow tract 
was anastomosed to the descending thoracic aorta. Postoperatively, we administered heparin intravenously for 2 
days after implantation, and then we administered warfarin sodium daily. We examined, both preoperatively and 
postoperatively, the serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), blood urea nitrogen 
(BUN), creatinine, lactate dehydrogenase (LDH), haptoglobin, fibrinogen, whole blood hemoglobin, hematocrit, 
prothrombin time (PT), partial thromboplastin time (PTT) and the plasma hemoglobin. We also recorded the 
assisted flow rate and the hemodynamic parameters of the animals. After IVAD implantation, the international 
normalized ratio (INR) was monitored and maintained in the range of 3.5-4.0. Postoperatively, when any device-
related problems developed, we euthanized the animals and performed autopsy. Results: After IVAD implantation, 
the 5 calves lived for 1, 6, 3, 12 and 21 days, respectively. Three of them were euthanized due to mechanical 
problems such as electrical shorts, and the other calves died suddenly due to blood leakage at the outflow tract on 
postoperative day 21 and graft disconnection on postoperative day 3, respectively. Autopsy was performed in all 
the animals and there was no evidence of thromboembolism or hemorrhage in the kidney, liver or lungs. There 
was also no evidence of thrombosis on the valve, blood sac or inflow/outflow tract. Hematologic and chemical 
examinations revealed mild hemolysis in the early postoperative period, which stabilized with minimal hemolysis. 
There was no organ dysfunction. Conclusion: Our newly developed Biomedlab® IVAD was feasible for im-
plantation and it functioned well in a calf model. Although there were 3 mechanical problems, we did not find 
any device-related thrombosis and serious hemolysis. With this encouraging result, it may be possible to perform 
animal experiments with the final version of IVAD, after correcting the mechanical problems, to evaluate the device’s 
longterm durability and stability. (Korean Circ J 2008;38:7-11) 
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Introduction 
 
The incidence of chronic heart failure is increasing 
due to both aging of the population and the improved 
medical management, and these factors allow more 
time for congestive heart failure (CHF) to develop. The 
therapeutic options are narrowed with the progression 
of this disease to terminal heart failure and cardiac 
transplantation then becomes an option, albeit an option 
of last resort.1)2) Although the recently developed ven-
tricular assist technology serves as a bridge to trans-
plantation, which permits cardiac rehabilitation, im-
provement of the heart and end-organ function and 
enhancement of the pre-transplant status, the hema-
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tologic effect of ventricular assist systems has not been 
clearly determined. 
In this study, we developed a new Biomedlab® elec-
tro-mechanical implantable ventricular assist device 
(IVAD) that is characterized by pulsatile blood flow 
assistance, smaller and lighter dimensions than that of 
its competitors and it is a wearable system (Table 1).3) 
We performed in vivo experimentation to evaluate the 
durability and safety of this device as well as its hema-
tologic effects. 
 
Materials and Methods 
 
Implantable left ventricular assist system 
The Biomedlab® IVAD is a ventricular assist device 
that is specifically designed to take over the pumping 
function of the left ventricle. The Biomedlab® IVAD 
consists of an implantable blood pump that contains 
an electric motor, and a blood sac and a driveline (Fig. 
1, 2). The driveline connects to a controller and to bat-
teries, which provide power to the pump. The system 
also includes a display module that displays pump in-
formation. The blood pump contains 2 mechanical Me-
dtronic Hall Prosthetic valves (Medtronic Inc. USA) as 
the inflow and outflow valves. The entire device weighs 
about 810 grams with dimensions of 97×59 mm. The 
blood sac is constructed of polyurethane and it col-
lapses for blood pumping when pushed by the motor. 
For inflow and outflow, 2 polyurethane tubes (3/16 
inch) were connected to the implantable pump and the 
tubes were extended with using a woven Dacron vas-
cular graft (Vascutek Ltd, Renfrewshire, Scotland) for 
aortic anastomosis. 
 
Implantation of the left ventricular assist device 
The animals used in this study were treated in com-
pliance with the “Guidelines for the care and Use of 
laboratory animals” prepared by the Institute of Labo-
ratory Animal Resources, the National Research Co-
uncil, and as published by the National Academy Press. 
Five calves weighing 60-80 kg were anesthetized 
(ketamine; 30 mg/kg administered intramuscularly, and 
isoflurane for maintenance of anesthesia; 2-4% inha-
lation) and the calves were mechanically ventilated after 
endotracheal intubation. With monitoring the blood 
pressure and electrocardiography, a left lateral thoraco- 
Table 1. Comparison of our prototype LVAD with the other available ventricular assist devices
HeartMate, TCI Novacor, Baxtor Biomedlab 
 
IP VE N100 N120 V1.7 V3.0 (expected) 
Pump output  
(L/min) 
 
12 
 
 
10 
 
 
10 
 
 
12 
 
 
7.4 (designed) 
5.5 (in vitro) 
7.8 (in vivo) 
10.0 
 
 
Dimensions (mm) ∅112×40 ∅112×40 140×160×50 ∅97×59 ∅110×50 
Weight (g) 570 908 1,000 810 700 
Stroke volume (cc) 083 083 70 90 053 070 
Blood contact Diaphragm Sac Sac 
LVAD: left ventricular assist device, TCI: thoratec corporation implantable, IP: implantable pneumatic, VE: vented electric 
   
Fig. 2. Inflow cuff, inflow cannula and outflow cannula.
Inlet tip 
Outlet tip 
Fig. 1. Implantable left ventricular device with the connecting
control tube. 
Pump connector 
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tomy was done with removal of the 5th rib and another 
left upper paramedian abdominal incision was made 
and dissection was performed to the preperitoneal space 
for creating pockets for implanting the IVAD. After 
injecting 10,000 units of heparin, the descending tho-
racic aorta below the level of the azygous vein was clamped 
with a Satinski-side biting clamp and the prepared Vas-
cutek graft was anastomosed with continuous 4-0 Pro-
lene (Ethicon, Inc. USA) suture for the outflow graft. 
The pericardium was incised and cradled. After injection 
of another 14,000 units of heparin, an arterial cannula 
was inserted into the proximal descending thoracic aorta 
and a venous cannula was inserted into the right atrium 
through the atrial appendage. Normothermic cardiopu-
lmonary bypass was instituted and the left ventricle 
was lifted by hand and the left ventricular apex was 
widely opened with a scalpel. Four 3-0 Prolene mattress 
sutures buttressed with felt were sutured at the four cor-
ners of the left ventricular (LV) apex and the inflow cuff 
was sutured with 12 mattress Prolene buttressed with felt. 
The IVAD was prepared to place in the preperitoneal 
cavity after filling the blood sac and cannulae with saline. 
The inflow cannula was prepared to insert from the 
prepared preperitoneal pocket and diaphragm hole. The 
inflow cannula tip was inserted into the left ventricule 
through the inflow cuff with removing the air. The con-
trol tube with power cable and vent line was connected 
to the control device. 
We implanted the Biomedlab® IVAD (Version 1.7) 
into the pre-peritoneal cavity in 5 calves. The inflow 
cannula was inserted through the left ventricular apex 
with the user-made inlet tip secured by a plastic cuff 
sewn onto the epicardial space, and the outflow tract 
was anastomosed to the descending thoracic aorta using 
a short segment of dacron graft. The diagram of the 
blood pump, the inlet and the outlet cannulae are shown 
in Fig. 1 and 2. The pump flow was monitored using an 
ultrasonic flow meter. 
After implantation of the IVAD, the calves were aw-
aked and their endotracheal tubes were removed at the 
operating room (Fig. 3). Early after the operation, the 
IVAD pump flow, the inflow and outflow pressure, the 
blood pressure, heart rate, pulmonary artery pressure and 
central venous pressure were continuously monitored. 
The IVAD flow and arterial pressure were continuously 
monitored from postoperative day 1. Intravenous hepa-
rin was administered continuously for 2 days after im-
plantation, and then warfarin sodium was administered 
daily to a target range between 3.0 and 4.0. We measured, 
both preoperatively and postoperatively, the serum as-
partate aminotransferase (AST), alanine aminotransferase 
(ALT), blood urea nitrogen (BUN), creatinine, lactate 
dehydrogenase (LDH), haptoglobin, fibrinogen, whole 
blood hemogloin, hematocrit, prothrombin time (PT), 
partial thromboplastin time (PTT) and plasma hemo-
globin. Postoperatively, when we found device-related 
problems, we then we euthanized the animals and per-
formed autopsy. The removed devices were grossly ob-
served, after gentle washing with saline, for whether there 
was a manufacture defect or thrombus in the blood con-
tact area. Three points of the luminal side of the sac 
were evaluated with scanning electron microscopy for 
intimal proliferation. 
 
Results 
 
The characteristics and outcomes of the five calves 
used in the experiments are shown in Table 2. After 
IVAD implantation, the 5 calves lived for 1, 6, 3, 12 and 
21 days, respectively. Three of them were euthanized 
due to mechanical problems such as electrical shorts, and 
the other 2 calves died suddenly due to blood leakage 
at the outflow tract on postoperative day 21 and graft 
disconnection on postoperative day 3, respectively. 
Hematologic and chemical studies revealed mild he-
molysis in the early postoperative period and this was 
stabilized with minimizing the hemolysis. However, 
there was no organ dysfunction seen on the blood che-
mistry (Table 3, 4). 
Autopsy was performed in all animals and there was 
Table 2. Characteristics and outcomes of the calves used in the experiment
Case Calf (kg) Survival record Flow rate (L/min) Cause of death Failure 
1 ♂, 60 6 days 0.8-2.0 Sacrifice Electrical 
2 ♂, 80 1 days 3.5-5.4 Reoperation Electrical 
3 ♂, 80 12 days 3.7-5.2 Sacrifice Electrical 
4 ♂, 82 3 days 3.5-4.9 Expire Graft disconnect 
5 ♂, 82 21 days 3.3-5.7 Sacrifice Pump failure 
 
Fig. 3. Calf after implanting the left ventricular assist system.
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no evidence of thromboembolism or hemorrhage in 
the kidney, liver or lungs. Post-explant examination of 
the pump also showed no evidence of thrombosis on 
the valve, blood sac or inflow/outflow tract (Fig. 3). 
However, there were small thrombi at the junction of 
the devices and the prosthetic inflow and outflow valves. 
On scanning electron microscopic examination, some 
platelets deposited with fibrin were seen at the inflow 
side of the blood sac; however, there were significant 
cellular and fibrin deposits at the outflow area of the 
blood sac (Fig. 4). 
 
Discussion 
 
As the number of patients with congestive heart fail-
ure increases, the use of left ventricular assist device 
(LVAD) in these patients is a growing issue worldwide. 
Many experimental and clinical studies have reported 
on LVAD implantation in patients with end-stage heart 
failure and some of these studies are still going on. One 
of the complications that can occur, although it is not 
common, with these LVADs is thrombosis within the 
left ventricle and adjacent to the device’s inflow conduit, 
which may lead to inflow obstruction and multiple th-
romboembolic events in other organs.4-8) Axial-flow pumps 
seem to result in new hemodynamic and hematologic 
characteristics that are not completely understood. The 
space between the pump inflow conduit and the left 
ventricular wall is thought to be vulnerable to thrombus 
formation. In this space, turbulent or stagnant flow may 
occur, and especially when filling of the left ventricle is 
impaired, as in patients with right-sided cardiac dysfunc-
Table 3. Changes of the hematologic and serum chemistry data
 Preop. (n=5) POD 1 (n=5) POD 7 (n=3) POD13 (n=2) POD 21 (n=1) 
PT (INR) 4.93 2.92 6.85 3.69 4.33 
Hb (g/dL) 10.9 11.8 8.5 8.6 5.8 
Hct (%) 30.8 37.3 27.9 28.7 18.9 
Plt (103/μL) 498 358 733 541 298 
BUN (mg/dL) 13.4 11 12.1 8.9 4.1 
Cr (mg/dL) 0.9 0.8 0.6 0.8 0.8 
t-bil (mg/dL) 0.1 0.2 0.1 0.1 0.1 
LDH (IU/L) 2314 5436 2455 2275 1791 
Plasma 4.3 7.9 7.4 3.8 7 
Free Hb (g/dL)      
Preop.: preoperative, POD: postoperative day, PT: prothrombin time, INR: international normalized ratio, Hb: hemoglobin, Hct: hema-
tocrit, plt: platelet, BUN: blood urea nitrogen, Cr: creatinine, t-bil: total bilirubin, LDH: lactate dehydrogenase 
 
Table 4. Changes of the reticulocyte count (103/μL) 
Case Preop. POD 1 POD 3 POD 5 POD 7 POD 14 POD 21
2 <0.1 <0.1      
3 <0.1   <0.1 <0.1 <0.1  
4 <0.4 <0.1 0.2     
5 <0.3   <0.2 <0.1 <0.1 <0.1 
Preop.: preoperative, POD: postoperative day 
 
A B C
Fig. 4. Gross and microscopic findings of removed blood sac. Removed blood sac for the gross findings (A) and scanning electron micro-
scopic findings at the inflow (B) and outflow (C) tracks from calf #4 (POD 13). POD: postoperative day. 
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tion. In addition, because LVAD recipients are often at 
a high risk for bleeding related to recent surgery or 
organ dysfunctions, it is difficult to achieve optimal an-
ticoagulation. Since the LVADs are used not only as a 
bridging therapy to transplantation, but also as a final 
therapy in recent days,9-13) it seems very important to 
determine their systemic hematologic effects. 
Current knowledge of thrombosis at biomaterial sur-
faces includes an understanding that protein adsorption, 
platelet adhesion and fibrin formation are each affected 
in their own ways by factors such as fluid mechanics 
and the biomaterial properties.8) The biological series 
of events that occur with blood contacting biomate-
rials is well documented and this has led to antiplatelet 
and anticoagulation therapy, which is now commonly 
used. Although many advances of anti-coagulation pro-
tocols and newer LVADs have been developed, thrombotic 
complications still occur that can cause patient mortality. 
Another major complication related to LVADs is bleed-
ing.14-16) Bleeding, which occurred in 68% of the LVAD 
patients in the mechanical circulatory support device 
(MCSD) database,17) may be due to excess anticoagulat-
ion that was originally intended to prevent thrombosis. 
In this experiment, we examined the changes of the 
postoperative hematologic laboratory findings as well 
as those of the organs and the explanted blood pump 
to evaluate the effects of thrombosis and hemolysis. 
There was no evidence of thrombosis or hemolysis in 
the explanted blood pump and cannulas, as well as in 
other organs. However, there are several limitations in 
this experiment. First, we evaluated only five calves, and 
this is a very small sample size for achieving reliable 
results. Second, since most of the calves died within a 
week, the mean values of the laboratory results are also 
not convincing. However, it may be said that there was 
no significant hemolytic and thrombotic complications 
that occurred in the early postoperative periods. There-
fore, further experimentation with a longer period and 
more subjects is necessary to confirm these results before 
conducting clinical trials. In addition, mechanical pro-
blems such as leakage of the devices and connector break-
age should be corrected. 
 
Conclusion 
We successfully performed a pre-clinical study of a 
newly developed Biomedlab® IVAD in a calf model. 
Although there were 3 mechanical problems, no throm-
bosis or hemolysis occurred in this study. There was 
only minimal hemolysis in the early postoperative periods 
and no evidence of thromboembolism in the major 
organs. However, significant research and development 
is still necessary to reduce the intimal proliferation at 
the inner surface of the blood sac. Since this experiment 
is limited by the small number of animals and their 
short duration of survival, further animal research with 
more subjects and a longer study period may be nece-
ssary to confirm our results. 
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